25E-NBOH

Hypertension, Coronary artery disease, Peripheral vascular disease, Structural heart defects

The NBOMe/NBOH class binds alpha-1A adrenoceptors (Ki < 1 µM, Rickli 2015), producing clinically significant vasoconstriction. Pre-existing cardiovascular disease dramatically increases the risk of hypertensive emergency, peripheral ischemia, and cardiac events. This interaction is pharmacologically intrinsic and dose-independent in character.

Amphetamine, Cocaine, MDMA, Methylphenidate

Combining 25E-NBOH with stimulants that produce sympathomimetic vasoconstriction creates additive cardiovascular risk. The alpha-1A adrenoceptor activity of NBOH compounds compounds with stimulant-induced catecholamine release, potentially producing dangerous hypertension and peripheral ischemia.

Epilepsy, History of seizures

Seizures are documented across multiple NBOMe compounds in clinical case series (Halberstadt 2017, Zawilska 2020). Individuals with pre-existing seizure disorders face compounded risk from class-level seizure threshold reduction.

Tramadol, Bupropion, High-dose antipsychotics

Given the documented seizure risk for the NBOMe/NBOH class, co-administration with agents that independently lower seizure threshold creates additive risk. No specific interaction data for 25E-NBOH exist.

Schizophrenia, Schizoaffective disorder, Family history of psychotic disorders

5-HT2A receptor agonism is established to precipitate acute psychosis in vulnerable individuals. Personal or family history of psychotic spectrum disorders represents a significant risk factor. No 25E-NBOH-specific incidence data exist.

Pregnancy, Breastfeeding

No reproductive toxicity data exist for 25E-NBOH or the NBOH class. 5-HT2A receptors play roles in neurodevelopment, and agonism during critical developmental windows poses unknown but theoretically concerning risk.

Concurrent MAOI use (irreversible or reversible)

Combination of a potent 5-HT2A/2C full agonist with monoamine oxidase inhibitors (phenelzine, tranylcypromine, moclobemide) creates mechanistically certain serotonin toxicity risk. No safe combination protocol exists. This is an absolute contraindication for all serotonergic psychedelics.

Concurrent lithium use

Case reports involving serotonergic psychedelics describe elevated seizure risk when combined with lithium. The mechanism is poorly characterized but may involve altered intracellular signalling downstream of 5-HT2A activation. Given the existing seizure risk of the NBOH class, this combination warrants avoidance.